The Use of Cholinesterase Inhibitors Across All Stages of Alzheimer's Disease (Q33165801)

23 July 2017

1 reference

title

The Use of Cholinesterase Inhibitors Across All Stages of Alzheimer's Disease (English)

1 reference

23 July 2017

0 references

William James Deardorff

series ordinal

1

1 reference

PubMed ID

26033268

23 July 2017

Eliahu Feen

series ordinal

2

1 reference

PubMed ID

26033268

23 July 2017

George T Grossberg

series ordinal

3

1 reference

23 July 2017

1 July 2015

1 reference

23 July 2017

1 reference

23 July 2017

32

1 reference

23 July 2017

7

1 reference

23 July 2017

537-547

1 reference

https://scigraph.springernature.com/pub.10.1007/s40266-015-0273-x

23 July 2017

0 references

cites work

2014 Alzheimer's disease facts and figures

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0273-X

Alzheimer disease in the United States (2010-2050) estimated using the 2010 census

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0273-X

The cholinergic hypothesis of Alzheimer's disease: a review of progress

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0273-X

Current pharmacologic treatment of dementia: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0273-X

Therapy for Alzheimer's Disease: How Effective are Current Treatments?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0273-X

Severe impairment battery. A neuropsychological test for severely demented patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0273-X

Effectiveness of Cholinesterase Inhibitors and Memantine for Treating Dementia: Evidence Review for a Clinical Practice Guideline

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0273-X

Tacrine. A cause of fatal hepatotoxicity?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0273-X

Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: A 24-week, randomized, double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0273-X

Evaluating the cognitive effects of donepezil 23 mg/d in moderate and severe Alzheimer's disease: analysis of effects of baseline features on treatment response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0273-X

Subgroup analysis of US and non-US patients in a global study of high-dose donepezil (23 mg) in moderate and severe Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0273-X

High-dose donepezil (23 mg/day) for the treatment of moderate and severe Alzheimer's disease: drug profile and clinical guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0273-X

How the FDA forgot the evidence: the case of donepezil 23 mg.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0273-X

Pharmacodynamic, pharmacokinetic and pharmacogenetic aspects of drugs used in the treatment of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0273-X

A review of compliance to treatment in Alzheimer's disease: potential benefits of a transdermal patch

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0273-X

Transdermal is better than oral: observational research of the satisfaction of caregivers of patients with Alzheimer's disease treated with rivastigmine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0273-X

A 24-week, multicentre, open evaluation of the clinical effectiveness of the rivastigmine patch in patients with probable Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0273-X

IDEAL: a 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0273-X

Effects of rivastigmine transdermal patch and capsule on aspects of clinical global impression of change in Alzheimer's disease: a retrospective analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0273-X

Efficacy of rivastigmine transdermal patch on activities of daily living: item responder analyses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0273-X

Randomized, double-blind, parallel-group, 48-week study for efficacy and safety of a higher-dose rivastigmine patch (15 vs. 10 cm²) in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0273-X

Responder analysis of a randomized comparison of the 13.3 mg/24 h and 9.5 mg/24 h rivastigmine patch

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0273-X

The ACTION study: methodology of a trial to evaluate safety and efficacy of a higher dose rivastigmine transdermal patch in severe Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0273-X

Galantamine--a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer's disease

21 January 2018

2 references

https://api.crossref.org/works/10.1007%2FS40266-015-0273-X

21 January 2018

12 December 2020

Current and emerging drug treatment options for Alzheimer's disease: a systematic review.

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0273-X

Size of the treatment effect on cognition of cholinesterase inhibition in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0273-X

Validity, significance, strengths, limitations, and evidentiary value of real-world clinical data for combination therapy in Alzheimer's disease: comparison of efficacy and effectiveness studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0273-X

Effectiveness of antidementia drugs in delaying Alzheimer's disease progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0273-X

Persistent treatment with cholinesterase inhibitors and/or memantine slows clinical progression of Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0273-X

Long-term outcome and prediction models of activities of daily living in Alzheimer disease with cholinesterase inhibitor treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0273-X

Syncope and its consequences in patients with dementia receiving cholinesterase inhibitors: a population-based cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0273-X

Cholinesterase inhibitors and hospitalization for bradycardia: a population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0273-X

Cholinesterase inhibitors and incidence of bradycardia in patients with dementia in the veterans affairs new England healthcare system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0273-X

Dementia medications and risk of falls, syncope, and related adverse events: meta-analysis of randomized controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0273-X

Withholding, discontinuing and withdrawing medications in dementia patients at the end of life: a neglected problem in the disadvantaged dying?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0273-X

Assessment of factors that influence physician decision making regarding medication use in patients with dementia at the end of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0273-X

Use of medications of questionable benefit in advanced dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0273-X

Acetylcholinesterase inhibitor and N-methyl-D-aspartic acid receptor antagonist use among hospice enrollees with a primary diagnosis of dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0273-X

Cholinesterase inhibitor and memantine use in newly admitted nursing home residents with dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0273-X

Cholinesterase inhibitor and N-methyl-D-aspartic acid receptor antagonist use in older adults with end-stage dementia: a survey of hospice medical directors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0273-X

Effect of discontinuing cholinesterase inhibitor therapy on behavioral and mood symptoms in nursing home patients with dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0273-X

Memantine ER, a once-daily formulation for the treatment of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0273-X

Memantine and cholinesterase inhibitors: complementary mechanisms in the treatment of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0273-X

Memantine in moderate to severe Alzheimer's disease: a meta-analysis of randomised clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0273-X

Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0273-X

Donepezil and memantine for moderate-to-severe Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0273-X

Tolerability and efficacy of memantine add-on therapy to rivastigmine transdermal patches in mild to moderate Alzheimer's disease: a multicenter, randomized, open-label, parallel-group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0273-X

The safety, tolerability, and efficacy of once-daily memantine (28 mg): a multinational, randomized, double-blind, placebo-controlled trial in patients with moderate-to-severe Alzheimer's disease taking cholinesterase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0273-X

Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0273-X

Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM-AD VA cooperative randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0273-X

Combination therapy for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0273-X

Benefits of combined cholinesterase inhibitor and memantine treatment in moderate-severe Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0273-X

Memantine in patients with Alzheimer's disease receiving donepezil: new analyses of efficacy and safety for combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0273-X

Memantine and cholinesterase inhibitor combination therapy for Alzheimer's disease: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0273-X

Long-term course and effectiveness of combination therapy in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0273-X

Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0273-X

Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0273-X

AD2000: design and conclusions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0273-X

AD2000: donepezil in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0273-X

The neuropharmacological basis for the use of memantine in the treatment of Alzheimer's disease

21 January 2018

2 references

https://api.crossref.org/works/10.1007%2FS40266-015-0273-X

21 January 2018

12 December 2020

Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0273-X

Strategies for continued successful treatment of Alzheimer's disease: switching cholinesterase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0273-X

The Effects of an Uninterrupted Switch from Donepezil to Galantamine without Dose Titration on Behavioral and Psychological Symptoms of Dementia in Alzheimer's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0273-X

Cognitive and affective changes in mild to moderate Alzheimer's disease patients undergoing switch of cholinesterase inhibitors: a 6-month observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0273-X

Effectiveness of switching to the rivastigmine transdermal patch from oral cholinesterase inhibitors: a naturalistic prospective study in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0273-X

Efficacy and safety of switching from oral cholinesterase inhibitors to the rivastigmine transdermal patch in patients with probable Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0273-X

Switching cholinesterase inhibitors in older adults with dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0273-X

Caregiver preference for rivastigmine patch relative to capsules for treatment of probable Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0273-X

Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease

21 January 2018

1 reference

12 December 2020

A 24-week, randomized, controlled trial of rivastigmine patch 13.3 mg/24 h versus 4.6 mg/24 h in severe Alzheimer's dementia

1 reference

12 December 2020

Combination therapy with cholinesterase inhibitors and memantine for Alzheimer's disease: a systematic review and meta-analysis

1 reference

12 December 2020

Realistic expectations for treatment success in Alzheimer's disease

1 reference

12 December 2020

Galantamine for Alzheimer's disease and mild cognitive impairment

1 reference

12 December 2020

Effects of galantamine in a 2-year, randomized, placebo-controlled study in Alzheimer's disease

1 reference

12 December 2020

A 24-Week, Open-Label Extension Study to Investigate the Long-term Safety, Tolerability, and Efficacy of 13.3 mg/24 h Rivastigmine Patch in Patients With Severe Alzheimer Disease

1 reference

12 December 2020

Cholinesterase inhibitors for Alzheimer's disease

1 reference

12 December 2020

The severe impairment battery: concurrent validity and the assessment of longitudinal change in Alzheimer's disease. The Alzheimer's Disease Cooperative Study.

1 reference

12 December 2020

Donepezil for dementia due to Alzheimer's disease

1 reference

12 December 2020

Rivastigmine for Alzheimer's disease

1 reference

12 December 2020

Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis

1 reference

12 December 2020

10.1007/S40266-015-0273-X

Identifiers

DOI

1 reference

23 July 2017

1 reference

PubMed ID

26033268